Search
for
Sort by
Research 421–450 of 1000+
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
- Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
- PKC downregulation upon rapamycin treatment attenuates mitochondrial disease
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- Gut instinct: Using tofacitinib to treat alopecia areata in the context of comorbid inflammatory bowel disease
- Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
- Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
- Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
- Baricitinib: A Review in Severe Alopecia Areata
- A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
- TOFACITINIB IN OVERLAPPING AUTOIMMUNE AND AUTOINFLAMMATORY DISORDERS: A CASE REPORT OF A DUAL GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME AND HIDRADENITIS SUPPURATIVA
- Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with <i>AIRE</i> gene mutation (autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy, APECED syndrome) treated with ruxolitinib
- Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
- Recalcitrant lichen planopilaris treated with upadacitinib: a case series
- 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- An Overview about Alopecia Areata Etiopathogenesis, Diagnosis, and Management: Review Article
- Skin Biology and Ageing
- P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
- Analyzing the role of tofacitinib in treatment of alopecia areata: A retrospective analysis from a tertiary care center of North India
- Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series
- Excellent response to tofacitinib treatment in a patient with alopecia universalis
- Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population
- Folliculitis decalvans responsive to tofacitinib: A case series
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- Alopecia universalis. Partial response to tofacitinib
- 1313 Fzd2 controls multiple aspects of epidermal development through distinct signaling mechanisms
- Treatment of severe alopecia areata with oral tofacitinib: A case series